{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:20:15Z","timestamp":1787671215630,"version":"build-2736575974"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.maturitas.2026.108982","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:42:37Z","timestamp":1779259357000},"page":"108982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-4788","authenticated-orcid":false,"given":"Valentina Elisabetta","family":"Bounous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Andronico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Suraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"D'Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Actis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.maturitas.2026.108982_bb0005","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0010","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"14","key":"10.1016\/j.maturitas.2026.108982_bb0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0020","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0030","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate","author":"Dwyer","year":"2026"},{"key":"10.1016\/j.maturitas.2026.108982_bb0035","series-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","author":"Carbine","year":"2018"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4476-1","article-title":"The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy","volume":"167","author":"Giannakeas","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"15","key":"10.1016\/j.maturitas.2026.108982_bb0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0055","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"2018","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"19","key":"10.1016\/j.maturitas.2026.108982_bb0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.maturitas.2026.108982_bb0065","series-title":"Long-term health consequences of premature or early menopause and considerations for management","author":"Faubion","year":"2015"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14740338.2020.1791818","article-title":"Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?","volume":"19","author":"Grandi","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/13697137.2024.2423213","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"27","author":"ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI","year":"2024","journal-title":"Climacteric"},{"issue":"31","key":"10.1016\/j.maturitas.2026.108982_bb0080","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"14","key":"10.1016\/j.maturitas.2026.108982_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143457","article-title":"Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1\/2 Genes Pathogenic Variants: Results from an Italian Survey","volume":"14","author":"Massarotti","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/GME.0000000000002201","article-title":"Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1\/2 mutation carriers","volume":"30","author":"DiSilvestro","year":"2023","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108982_bb0100","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/pon.5714","article-title":"BRCA mutation carriers\u2019 perceptions on postmenopausal hormone therapy: An Italian study","volume":"30","author":"Grandi","year":"2021","journal-title":"Psychooncology"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/AOG.0000000000006226","article-title":"Elimination of the Black Box Warning on menopausal hormone therapy","volume":"147","author":"Sriprasert","year":"2026","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/13697137.2025.2585487","article-title":"International Menopause Society (IMS) recommendations and key messages on women\u2019s midlife health and menopause","volume":"28","author":"Panay","year":"2025","journal-title":"Climacteric"},{"issue":"9","key":"10.1016\/j.maturitas.2026.108982_bb0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of Risk-Reducing Surgery in Mutation Carriers With Cancer Risk and Mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.maturitas.2026.108982_bb0120","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.maturitas.2026.108982_bb0125","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/GME.0000000000002254","article-title":"Long-term effects of premenopausal bilateral oophorectomy with or without hysterectomy on physical aging and chronic medical conditions","volume":"30","author":"Mielke","year":"2023","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108982_bb0130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/AOG.0000000000003729","article-title":"Clinical Effects of Early or Surgical Menopause","volume":"135","author":"Kingsberg","year":"2020","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108982_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","article-title":"Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses\u2019 Health Study","volume":"121","author":"Parker","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"22","key":"10.1016\/j.maturitas.2026.108982_bb0140","doi-asserted-by":"crossref","first-page":"15931","DOI":"10.18632\/oncotarget.24638","article-title":"Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?","volume":"9","author":"Ben-Aharon","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"11","key":"10.1016\/j.maturitas.2026.108982_bb0150","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14469","article-title":"Premenopausal bilateral oophorectomy and Alzheimer\u2019s disease imaging biomarkers later in life","volume":"21","author":"Kantarci","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0165","first-page":"705","article-title":"Mechanisms of Estrogen Effects on the Endothelium: An Overview","volume":"30","author":"Chakrabarti","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/cancers15030711","article-title":"Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review","volume":"15","author":"Nitschke","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0175","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ygyno.2021.06.022","article-title":"Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study","volume":"162","author":"Valle","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0180","article-title":"Prevalence of cardiometabolic outcomes in women who underwent salpingo-oophorectomy to prevent hereditary breast and ovarian cancer: a meta-analysis","volume":"24","author":"Moraes","year":"2024","journal-title":"Fam. Cancer"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0185","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncomms1601","article-title":"BRCA1 is an essential regulator of heart function and survival following myocardial infarction","volume":"2","author":"Shukla","year":"2011","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010764","article-title":"The role of hormonal replacement therapy in BRCA mutated patients: lights and shadows","volume":"24","author":"Loizzi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"28","key":"10.1016\/j.maturitas.2026.108982_bb0195","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030313","article-title":"Concerns and expectations of risk-reducing surgery in women with hereditary breast and Ovarian Cancer Syndrome","volume":"8","author":"Modaffari","year":"2019","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-8258(03)00072-6","article-title":"Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy","volume":"89","author":"Robson","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"3\/4","key":"10.1016\/j.maturitas.2026.108982_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1021119405814","article-title":"Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer","volume":"1","author":"Elit","year":"2001","journal-title":"Fam. Cancer"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8420","article-title":"Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation","volume":"2","author":"Kotsopoulos","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/bjc.2011.202","article-title":"Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT","volume":"105","author":"Challberg","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2217\/WHE.12.41","article-title":"BRCA Carriers, Prophylactic Salpingo-Oophorectomy and Menopause: Clinical Management Considerations and Recommendations","volume":"8","author":"Finch","year":"2012","journal-title":"Women Health"},{"key":"10.1016\/j.maturitas.2026.108982_bb0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2022.08.008","article-title":"Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group","volume":"166","author":"Mendoza","year":"2022","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case\u2013control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0240","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0245","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0250","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00432-021-03629-z","article-title":"Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review","volume":"147","author":"Huber","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0255","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/13697137.2016.1209396","article-title":"Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation","volume":"19","author":"Guidozzi","year":"2016","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/GME.0000000000002136","article-title":"Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients","volume":"30","author":"Pederson","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.108982_bb0265","first-page":"46","article-title":"Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carrier. Best practice & research","volume":"65","author":"Gaba","year":"2020","journal-title":"Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00198-020-05608-5","article-title":"Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study)","volume":"32","author":"Jiang","year":"2021","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0275","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/13697137.2012.656401","article-title":"The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective","volume":"15","author":"Hodis","year":"2012","journal-title":"Climacteric"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108982_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11883-018-0758-2","article-title":"Emerging Research on the Implications of Hormone Replacement Therapy on Coronary Heart Disease","volume":"20","author":"Keck","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0290","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/GME.0000000000001553","article-title":"The Women\u2019s Health Initiative trials of menopausal hormone therapy: lessons learned","volume":"27","author":"Manson","year":"2020","journal-title":"Menopause"},{"issue":"9","key":"10.1016\/j.maturitas.2026.108982_bb0295","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-024-05936-7","article-title":"The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer","volume":"150","author":"Ortmann","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0300","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.16896","article-title":"Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.maturitas.2026.108982_bb0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2021.02.007","article-title":"Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy","volume":"148","author":"Michaelson-Cohen","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108982_bb0310","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2026.108982_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2025.108208","article-title":"Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases","volume":"195","author":"Ram\u00edrez","year":"2025","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0320","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jmig.2020.11.023","article-title":"Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis","volume":"28","author":"Matanes","year":"2021","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"11","key":"10.1016\/j.maturitas.2026.108982_bb0325","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women WithBRCA Mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0330","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian Cancer Prevention and Screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2009.12.023","article-title":"Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?","volume":"117","author":"Cass","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/aogs.13120","article-title":"Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy","volume":"96","author":"Johansen","year":"2017","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.maturitas.2026.108982_bb0345","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13697137.2023.2173567","article-title":"BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians\u2019 recommendations","volume":"26","author":"Armon","year":"2023","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0350","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e70","article-title":"Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey","volume":"35","author":"Palaia","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0355","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/1471-0528.17511","article-title":"Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: scoping review and international consensus recommendations","volume":"130","author":"Nebgen","year":"2023","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0360","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/jsm.12713","article-title":"Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention","volume":"12","author":"Bober","year":"2014","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.maturitas.2026.108982_bb0365","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3390\/curroncol30020185","article-title":"The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication","volume":"30","author":"Alves-Nogueira","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.maturitas.2026.108982_bb0370","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2017.07.018","article-title":"Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: a prospective study","volume":"84","author":"Vermeulen","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0375","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.maturitas.2026.108982_bb0380","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/jsxmed\/qdaf183","article-title":"Sexual functioning after risk-reducing oophorectomy: a prospective study","volume":"22","author":"Rowen","year":"2025","journal-title":"J. Sex. Med."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108982_bb0385","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ajog.2023.03.045","article-title":"Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis","volume":"229","author":"Wei","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108982_bb0390","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women\u2019s Health Initiative Randomized Clinical Trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"issue":"10204","key":"10.1016\/j.maturitas.2026.108982_bb0395","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.maturitas.2026.108982_bb0400","doi-asserted-by":"crossref","DOI":"10.23736\/S0026-4784.19.04469-1","article-title":"Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Societ\u00e0 Italiana per la Menopausa (SIM) and the Societ\u00e0 Italianadella Terza Et\u00e0 (SIGiTE)","volume":"71","author":"Cagnacci","year":"2019","journal-title":"Minerva Ginecol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0405","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/humupd\/dmab026","article-title":"Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice","volume":"27","author":"Genazzani","year":"2021","journal-title":"Hum. Reprod. Update"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0410","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/COC.0000000000000269","article-title":"Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?","volume":"41","author":"Birrer","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0415","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","article-title":"Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement","volume":"157","author":"Sinno","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0420","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-8587(25)00394-8","article-title":"Menopausal hormone treatment and breast cancer","volume":"14","author":"Gompel","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0425","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/AOG.0000000000004723","article-title":"Menopausal Hormone Therapy Formulation and Breast Cancer Risk","volume":"139","author":"Abenhaim","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0430","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","article-title":"Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy","volume":"81","author":"Magnusson","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108982_bb0435","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study","volume":"114","author":"Cold, MD","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0440","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"20","key":"10.1016\/j.maturitas.2026.108982_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14207328","article-title":"Estradiol and micronized progesterone: a narrative review about their use as hormone replacement therapy","volume":"14","author":"Foschi","year":"2025","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.maturitas.2026.108982_bb0450","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jama.2019.10692","volume":"322","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.genm.2011.03.008","article-title":"Treating menopausal symptoms with a tissue-selective estrogen complex","volume":"8","author":"Levine","year":"2011","journal-title":"Gend. Med."},{"key":"10.1016\/j.maturitas.2026.108982_bb0460","series-title":"Effects of Bazedoxifene\/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial","author":"Pinkerton","year":"2014"},{"issue":"8","key":"10.1016\/j.maturitas.2026.108982_bb0465","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/GME.0000000000002217","article-title":"Comparative safety of conjugated estrogens\/bazedoxifene versus estrogen\/progestin combination hormone therapy among women in the United States: a multidatabase cohort study","volume":"30","author":"Hoffman","year":"2023","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0470","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Harvey","year":"2013","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.maturitas.2026.108982_bb0475","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s43032-023-01295-9","article-title":"Tibolone and Breast Tissue: a Review","volume":"30","author":"Lello","year":"2023","journal-title":"Reprod. Sci."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0480","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/nedt.2006.2.3.299","article-title":"Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women","volume":"2","author":"Genazzani","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108982_bb0485","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/2053369119876490","article-title":"Progestogens are the problem in hormone replacement therapy: Time to reappraise their use","volume":"26","author":"Manyonda","year":"2020","journal-title":"Post Reprod Health"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0490","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00404-022-06647-5","article-title":"Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review","volume":"307","author":"Gold\u0161tajn","year":"2023","journal-title":"Arch. Gynecol. Obstet."},{"issue":"10","key":"10.1016\/j.maturitas.2026.108982_bb0495","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamainternmed.2017.3877","article-title":"Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS)","volume":"177","author":"Taylor","year":"2017","journal-title":"JAMA Intern. Med."},{"issue":"9","key":"10.1016\/j.maturitas.2026.108982_bb0500","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","volume":"20","year":"2013","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0505","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets","volume":"13","author":"Eugster-Hausmann","year":"2010","journal-title":"Climacteric"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108982_bb0510","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study","volume":"114","author":"Cold","year":"2022","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108982_bb0515","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0520","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108982_bb0525","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus","volume":"138","year":"2021","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108982_bb0530","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/2053369120956636","article-title":"The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis","volume":"26","author":"Marsden","year":"2020","journal-title":"Post Reprod Health"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:40:32Z","timestamp":1787668832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226001593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":106,"alternative-id":["S0378512226001593"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108982","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108982"}}